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MyelinAbstract Neurofibromatosis type I (NF1) is an autosomal dominant disorder with involvement of
both the cutaneous and nervous systems. Patients are susceptible to neurological complication in
the form of tumors of the brain and spinal cord. Multiple sclerosis (MS) is a chronic autoimmune
disease that affects the myelinated axons in the central nervous system. Unlike MS, none of the neu-
rological complications of NF1 is demyelinating. The association of these two diseases in the same
patient is rare and could be genetically related. Early detection of the presence of MS in patients
with NF1 is of utmost importance as treatment will certainly decrease further neurological disabil-
ity. Here we report the first Egyptian lady with this association.
 2016 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neurofibromatosis type I (NF1) is considered a neurocuta-
neous autosomal dominant disorder characterized by cafe-
au-lait spots, eye Lisch nodules, and skin fibromatous tumors
with increased susceptibility to tumor formation whether
benign or malignant. The worldwide incidence of NF1 is 1 in
2500 to 1 in 3000 [1]. The prevalence in Egypt is unknown.
Multiple sclerosis (MS), on the other hand, is an immune
mediated inflammatory disorder causing progressive demyeli-
nation of the brain and spinal cord [2]. The association of these
disorders is rare and exclusive and has been previously
reported [3–13]. Although both diseases affect the neurologicalsystem, only MS is potentially treatable and therefore early
recognition of this association is of utmost importance.
2. Case presentation
We report a 32 year old female of healthy non consanguineous
parents who presented to the genetics clinic because her son
had multiple café au lait patches. Both (mother and son) were
diagnosed with NF1 on the basis of the National Institutes of
Health Diagnostic Criteria for NF1 [14]. The mother has mul-
tiple café au lait spots (more than 6) on various parts of her
body, axillary freckling and multiple cutaneous neurofibromas
all over her body while the child showed delayed speech, vari-
able sized hyperpigmentation patches over all the body noticed
since birth, the largest was over his abdomen.
Two years before presentation, the mother developed a
sense of pins and needles in lower limbs up to her knees. It
Figure 1 MRI brain of patient showing multiple variable sized
patchy areas of abnormal signal intensity that were seen in both
periventricular regions, both centrum semi ovale, right middle
cerebellar peduncle and right side of mid brain.
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days later. This was associated with sense of swollenness as if
walking on soft ground. She also reported difficulty in passing
urine while the desire of micturition remained intact. She sought
medical advice and over the counter drugs were prescribed to
her (she could not remember their names) after which she felt a
partial improvement. One and a half years later, she developed
a sense of severe lancinating pain followed by a sense of pins
and needles on her right side of the face including the tongue last-
ing for 1 h, then resolved spontaneously. This attack was repeated
nearly three times in one month. Two months later, she developed
swaying of gait with tendency to fall to either side not related to
dim light. This was followed by bilateral lower limbs weakness left
more than right, distal more than proximal with no change in tone
but again she felt the pins and needles and as if she walked on soft
ground. Few days later, she reported passing few drops of urine
before reaching an appropriate place with no post voiding satis-
faction. Through the past 6 months, she started to develop short
term memory loss with intact long term memory. There was no
other motor, sensory, cranial, or cerebellar affection.
On examination, the patient had multiple café au lait patches
all over her body sparing the face, axillary freckling, and multiple
cutaneous neurofibromas. She was fully conscious, oriented to
time, place and person with intact recent and remote memory.
She had fluent speech with no dysarthria or dysphasia.
Cranial nerve examination showed decreased visual acuity
of the left eye counting fingers at 1 m, sluggish reactive left
pupil to light. Left horizontal jerky nystagmus. No other cra-
nial nerve affection. Motor power 5/5 bilateral normal tone,
brisk deep tendon reflexes, bilateral extensor planter, lost
abdominal reflexes with no muscle atrophy. Superficial sensa-
tion was lost till the level of thoracic vertebrae D7. Coordina-
tion tests were intact and she had normal gait.
Complete blood count (CBC) and erythrocyte sedimenta-
tion rate (ESR) were normal. Antinuclear antibodies test
(ANA) and double stranded DNA were negative. Slit lamp
showed Leish nodules while fundus examination and EEG
were unremarkable Electromyogram (EMG) and nerve con-
duction velocity (NCV) showed no abnormalities.
Auditory evoked potential revealed a right sided demyelinating
lesion at the pontomesencephalic region while visual evoked
potential revealed normal retino-cortical pathway. CSF analysis
showed only albumin band with no detected oligoclonal band.
MRI brain exhibited multiple variable sized patchy areas of
abnormal signal intensity in both periventricular regions, both
centrum semi ovale, right middle cerebellar peduncle and right
side of mid brain (Figs. 1 and 2). MRI of cervico dorsal spine
revealed multiple patchy enhancing intra medullary abnormal
signal along the whole cord, (Fig. 3).
Expanded Disability Status Scale assessment for MS [14]
revealed the following: Visual: 3 (p) due to Leish nodules,
Cerebral: 0, Cerebellar: 0, Pyramidal: 1, Brain stem: 1, Sen-
sory: 2, Sphincter: 0, Ambulation: 0, Total: 2.5.
The patient received corticosteroids and had a good
response regarding improvement of her symptoms after two
months of treatment.3. Discussion
Here we report the first Egyptian patient with both NF1 and
MS. The diagnosis of NF1 was made according to the clinicalcriteria suggested by the National Institutes of Health Consen-
sus Development Conference on Neurofibromatosis [14] while
the diagnosis of MS was based on both clinical and radiolog-
ical findings [15,16]. Although NF1 complications involve pri-
marily the neurological system (including tumors like gliomas
and glioblastomas), none of these lesions has a demyelinating
nature similar to what our patient experienced and so required
further investigations one of which was the MRI brain which
were highly suggestive of MS.
There are 4 types of MS: Relapsing-Remitting MS (RRMS)
is the most common in which patients have alternating periods
Figure 2 MRI brain of patient showing multiple variable sized
patchy areas of abnormal signal intensity that were seen in both
periventricular regions, both centrum semi ovale, right middle
cerebellar peduncle and right side of mid brain.
Figure 3 MRI of cervico dorsal spine showing multiple patchy
enhancing intra medullary abnormal signal along the whole cord.
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occur followed by remissions (complete recovery-symptoms
free) periods. The second type is the secondary progressive
where patients worsen over times with or without relapses
and remissions. The third type is the primary progressive from
the start which is also progressive in nature but without
relapses and remissions. The rarest type is the progressive
relapsing MS which is also progressive in nature from the start
with acute relapses and no remissions [17].
The course of the disease in our patient indicates a relapsing
remittent MS in which the patient had alternating periods of
exacerbations and symptom free periods. This is in contrast
to previous reports where the primary progressive type is the
most common form of MS reported in NF1 patients.
[3,6,8,10,12]. Interestingly, patients with PRMS and NF1
originated from Iran and Italy both countries have historical
backgrounds with Egypt [7,10,11,13].
The hypothesis of this association was based on that some
MS-NF1 patients have a mutation in the oligodendrocyte mye-
lin glycoprotein (OMgp) gene. This gene has a role in myelina-
tion and embedded within the intron of the NF1 gene [18].
This gene might be a target antigen to the autoimmune attacks
of demyelinating diseases like MS. Hinks et al., found a single
point mutation in OMgp gene (resulted in an amino-acid
change of glycine to aspartic acid) in patients with MS [19].Against this theory, patients with the primary progressive
MS form and NF1 did not have this mutation [6].
Another suggested theory was that NF1 mutation can cause
uncontrolled Schwann cell proliferation due to lack of suppres-
sion gene and so might cause unsuppressed response of the
immune system (autoimmune) to CNS myelin in susceptible
patients [7].
In conclusion, demyelination is not a part of the disease
course of NF1 patients and so any unusual symptom has to
be thoroughly investigated. MS could be associated with
NF1 with the primary progressive form more than relapsing
remittent form. Both NF1 and MS could be genetically related
but need further advanced studies like whole exom/genome
sequencing on a larger number of patients to be evaluated.
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